Sarah Cannon Research Institute, Nashville, TN 37203, USA.
Cancer Invest. 2011 Aug;29(7):451-5. doi: 10.3109/07357907.2011.590568. Epub 2011 Jun 22.
To evaluate the activity of panobinostat in refractory renal carcinoma.
Patients with advanced clear cell renal carcinoma who had received previous therapy with at least one angiogenesis inhibitor and one mTOR inhibitor were treated with panobinostat 45 mg orally twice a week, and were reevaluated after 8 weeks.
Twenty patients were treated with no objective responses. All patients progressed or stopped treatment prior to the 16-week reevaluation. Panobinostat was generally well-tolerated.
Panobinostat had no activity in this group of patients with refractory renal carcinoma. Further development of panobinostat in renal carcinoma is not recommended.
评估帕比司他在难治性肾细胞癌中的活性。
接受过至少一种血管生成抑制剂和一种 mTOR 抑制剂治疗的晚期透明细胞肾细胞癌患者，给予帕比司他 45 毫克口服，每周两次，8 周后重新评估。
20 例患者无客观缓解。所有患者在 16 周重新评估前进展或停止治疗。帕比司他总体耐受性良好。
帕比司他在难治性肾细胞癌患者中无活性。不推荐进一步开发帕比司他治疗肾细胞癌。
